Company: SHPH
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001493152-25-008462
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01 Entry into a Material Definitive Agreement.

On
February 26, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “ Company”), entered into an amendment
agreement (the “ Amendment Agreement”) for purposes of amending the terms of the Securities Purchase Agreement, originally
dated January 11, 2023 (the “ SPA”), and as amended May 10, 2023, June 5, 2023 and August 6, 2024, between the Company and
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (the “ Holder”), in its capacity as the registered
holder of a warrant to purchase 1,018,079 shares of common stock (127,260 post reverse split) (the “ Alto Warrant”)
and formerly holder of a $4.3 million convertible note (the “ Note”), both of which had been issued by the Company and the
Company’s wholly owned subsidiary, Shuttle Pharmaceuticals, Inc., as guarantor.

Under
the Amendment Agreement, in exchange for the Company’s payment of $75,000 to the Holder, the Holder agreed (1) to permanently waive
its right to purchase up to $10 million in Additional Notes and Additional Warrants, as such term is defined in Section 5 of the
May 10, 2023 amendment, and (2) to a one-time waiver of the Holder’s right to participate in the Company’s contemplated
registered securities offering, as disclosed in the Company’s registration statement on Form S-1 (SEC File No. 333-284889), filed
with the SEC on February 13, 2025.

The
foregoing description of the Amendment Agreement does not purport to be complete and is qualified in its entirety by reference to the
full text of the Amendment Agreement, which agreement is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item
9.01 Financial Statements and Exhibits.